Purple Biotech Ltd.
PPBTHealthcare|Biotechnology|IL
$1.31
+0.06 (+4.80%)
DCF Value
$1.39
Tangible Book / Share
$0.45
Cash / Share
$0.56
Financials
Financial Snapshot
Market Cap
$180.9K
Enterprise Value
$5.1M
Revenue (TTM)
$0.00
Net Income (TTM)
-$24.5M
Cash & Investments
$6.1M
Net Cash
$6.0M
Free Cash Flow (TTM)
-$7.8M
Operating CF (TTM)
-$7.8M
Debt/Equity
0.01
Cash Runway & Burn Rate
Cash on Hand
$6.1M
Quarterly Burn
$1.9M
Monthly Burn
$646.5K
Est. Runway
~3.1 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $14.7M | $3.9M | $5.2M | $6.4M | $57.8M | $47.2M | $32.1M | $15.4M | $8.5M | $9.6M | $6.1M | |
| Operating Cash Flow | -$6.3M | -$8.6M | -$8.5M | -$5.6M | -$12.1M | -$15.3M | -$16.7M | -$19.9M | -$14.4M | -$5.5M | -$7.8M | |
| Free Cash Flow | -$6.3M | -$8.6M | -$8.5M | -$5.6M | -$12.2M | -$15.4M | -$17.0M | -$19.9M | -$14.4M | -$5.5M | -$7.8M | |
| Capital Expenditure | -$10.0K | -$13.0K | -$16.0K | -$11.0K | -$156.0K | -$115.0K | -$228.0K | -$3.0K | $0.00 | -$3.0K | $0.00 | |
| Financing Cash Flow | $10.4M | $3.0M | $7.8M | $5.2M | $68.5M | $1.5M | $1.1M | $5.4M | $6.8M | $6.4M | $7.9M |
R&D Spending
R&D (TTM)
$4.3M
R&D Intensity
—
R&D Growth vs Prior
+16.5%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $100.0K | $1.0M | $1.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $4.2M | $4.6M | $5.3M | $2.3M | $7.3M | $11.8M | $16.3M | $17.0M | $7.6M | $3.7M | $4.3M | |
| R&D % of Revenue | — | 4640.0% | 526.8% | 227.8% | — | — | — | — | — | — | — | |
| SG&A | $3.0M | $6.4M | $5.2M | $6.1M | $5.8M | $5.8M | $6.0M | $4.8M | $2.9M | $3.0M | $3.3M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $100.0K | $1.0M | $1.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $80.00 | $236.6K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $100.0K | $1.0M | $999.9K | -$236.6K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $4.2M | $4.6M | $5.3M | $2.3M | $7.3M | $11.8M | $16.3M | $17.0M | $7.6M | $3.7M | $4.3M | |
| SG&A | $3.0M | $6.4M | $5.2M | $6.1M | $5.8M | $5.8M | $6.0M | $4.8M | $2.9M | $3.0M | $3.3M | |
| Operating Income | -$7.2M | -$12.0M | -$7.8M | -$7.2M | -$13.3M | -$17.9M | -$22.6M | -$22.3M | -$11.0M | -$27.5M | -$28.4M | |
| Interest Expense | $6.0K | $26.0K | $9.0K | $181.0K | $56.4K | $79.0K | $67.0K | $56.0K | $41.0K | $39.0K | $68.0K | |
| Pretax Income | -$12.1M | -$12.9M | -$5.6M | -$5.9M | -$28.9M | -$17.8M | -$21.8M | -$20.0M | -$7.3M | -$26.5M | -$24.6M | |
| Net Income | -$12.1M | -$12.2M | -$5.2M | -$5.8M | -$28.2M | -$18.4M | -$21.7M | -$19.9M | -$7.2M | -$26.4M | -$24.5M | |
| EPS (Diluted) | -422.00 | -258.00 | -74.00 | -56.00 | -50.00 | -20.00 | -24.00 | -17.96 | -4.42 | -5.50 | -2.22 | |
| EBITDA | -$7.0M | -$12.9M | -$5.6M | -$6.1M | -$13.1M | -$17.5M | -$21.5M | -$19.7M | -$7.1M | -$26.3M | -$24.3M | |
| Shares Out. (M) | 0.03 | 0.05 | 0.07 | 0.10 | 0.58 | 0.88 | 0.90 | 1.11 | 1.64 | 4.80 | 10.86 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.8M | $3.9M | $5.2M | $4.4M | $11.2M | $10.9M | $15.0M | $14.5M | $7.4M | $8.7M | $5.2M | |
| Short-Term Investments | $7.9M | $0.00 | $0.00 | $2.0M | $46.6M | $36.3M | $17.1M | $923.0K | $1.1M | $857.0K | $869.0K | |
| Total Current Assets | $14.9M | $8.0M | $8.5M | $8.3M | $59.3M | $48.5M | $33.3M | $15.8M | $8.9M | $9.9M | $6.6M | |
| Total Assets | $14.9M | $14.2M | $14.7M | $14.7M | $83.8M | $70.2M | $54.6M | $44.3M | $37.0M | $17.6M | $14.2M | |
| Total Current Liabilities | $1.3M | $4.1M | $3.3M | $3.5M | $3.1M | $4.3M | $7.1M | $9.7M | $4.0M | $7.8M | $1.8M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $1.5M | $5.6M | $3.7M | $3.9M | $4.1M | $5.1M | $7.5M | $10.0M | $4.1M | $7.9M | $2.0M | |
| Stockholders' Equity | $13.4M | $7.3M | $10.5M | $10.4M | $79.4M | $64.8M | $46.9M | $34.2M | $32.9M | $9.7M | $12.3M | |
| Retained Earnings | -$26.2M | -$38.6M | -$43.7M | -$49.5M | -$77.5M | -$95.9M | -$117.6M | -$137.5M | -$144.7M | -$171.1M | -$170.7M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$6.3M | -$8.6M | -$8.5M | -$5.6M | -$12.1M | -$15.3M | -$16.7M | -$19.9M | -$14.4M | -$5.5M | -$7.8M | |
| Capital Expenditure | -$10.0K | -$13.0K | -$16.0K | -$11.0K | -$156.0K | -$115.0K | -$228.0K | -$3.0K | $0.00 | -$3.0K | $0.00 | |
| Free Cash Flow | -$6.3M | -$8.6M | -$8.5M | -$5.6M | -$12.2M | -$15.4M | -$17.0M | -$19.9M | -$14.4M | -$5.5M | -$7.8M | |
| Investing Cash Flow | -$7.9M | $2.8M | $2.0M | -$449.0K | -$49.6M | $13.4M | $19.9M | $13.9M | $509.0K | $449.5K | $314.0K | |
| Financing Cash Flow | $10.4M | $3.0M | $7.8M | $5.2M | $68.5M | $1.5M | $1.1M | $5.4M | $6.8M | $6.4M | $7.9M | |
| Issuance of Stock | $6.3M | $2.4M | $4.7M | $2.6M | $27.9M | $1.8M | $1.5M | $1.6M | $5.8M | $6.6M | $4.8M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | -$171.0K | -$179.0K | -$153.0K | -$165.0K | -$168.0K | -$183.0K | -$217.0K | -$250.0K | |
| Stock Based Comp. | $400.0K | $2.3M | $773.0K | $1.3M | $2.6M | $2.1M | $2.4M | $1.9M | $582.0K | $309.0K | $317.0K | |
| Net Change in Cash | -$3.8M | -$2.8M | $1.2M | -$778.0K | $6.9M | -$357.0K | $4.1M | -$541.0K | -$7.1M | $1.3M | $500.0K |
Dilution Tracker
Shares outstanding grew 734.9% over 5 years — significant dilution
Shares Outstanding
0M
5-Year Share Growth
+734.9%
Stock Issuance (TTM)
$4.8M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.03 | 0.05 | 0.07 | 0.10 | 0.58 | 0.88 | 0.90 | 1.11 | 1.64 | 4.80 | 10.86 | |
| Change vs Prior % | — | 64.3% | 50.2% | 36.3% | 493.8% | 52.8% | 2.9% | 22.4% | 48.2% | 192.8% | 126.2% | |
| Stock Issuance | $6.3M | $2.4M | $4.7M | $2.6M | $27.9M | $1.8M | $1.5M | $1.6M | $5.8M | $6.6M | $4.8M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $400.0K | $2.3M | $773.0K | $1.3M | $2.6M | $2.1M | $2.4M | $1.9M | $582.0K | $309.0K | $317.0K |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | 100.0% | 100.0% | 100.0% | — | — | — | — | — | — | — | |
| Operating Margin % | — | -11966.0% | -782.6% | -715.6% | — | — | — | — | — | — | — | |
| Net Margin % | — | -12177.0% | -520.0% | -585.0% | — | — | — | — | — | — | — | |
| EBITDA Margin % | — | -12883.0% | -555.3% | -613.6% | — | — | — | — | — | — | — | |
| FCF Margin % | — | -8640.0% | -849.6% | -559.2% | — | — | — | — | — | — | — | |
| ROE % | -90.6% | -166.5% | -49.4% | -56.1% | -35.5% | -28.4% | -46.2% | -58.1% | -22.0% | -271.6% | -151.8% | |
| ROA % | -81.3% | -85.9% | -35.3% | -39.7% | -33.6% | -26.2% | -39.7% | -44.9% | -19.5% | -150.2% | -172.9% | |
| ROIC % | -52.7% | -118.3% | -68.6% | -62.9% | -16.5% | -27.1% | -47.3% | -64.0% | -33.1% | -272.9% | -241.9% | |
| R&D / Revenue % | — | 4640.0% | 526.8% | 227.8% | — | — | — | — | — | — | — |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 900.0% | 0.0% | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 900.0% | -0.0% | -123.7% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | -76.5% | -66.6% | 34.6% | 8.6% | -86.3% | -34.5% | -26.0% | 1.5% | 50.6% | -149.5% | |
| Net Income | -188.6% | -0.4% | 57.3% | -12.5% | -382.0% | 34.8% | -17.9% | 8.3% | 63.6% | -264.4% | |
| EPS (Diluted) | 51.7% | 38.9% | 71.3% | 24.3% | 10.7% | 60.0% | -20.0% | 25.2% | 75.4% | -24.4% | |
| Operating Cash Flow | -89.3% | -37.8% | 1.7% | 34.2% | -116.7% | -26.1% | -9.7% | -19.1% | 27.9% | 61.5% | |
| Free Cash Flow | -89.1% | -37.8% | 1.7% | 34.2% | -119.0% | -25.5% | -10.4% | -17.5% | 27.9% | 61.4% | |
| R&D Expense | 63.3% | 11.0% | 13.5% | -56.8% | 220.0% | 62.3% | 38.0% | 4.4% | -55.3% | -51.0% | |
| SG&A Expense | 99.0% | 112.9% | -18.8% | 17.2% | -4.5% | 0.3% | 2.4% | -18.8% | -39.4% | 1.6% | |
| Total Assets | 37.9% | -4.9% | 3.8% | -0.0% | 469.4% | -16.2% | -22.2% | -18.9% | -16.4% | -52.6% | |
| Book Value / Share | -76.3% | -60.9% | -14.8% | -33.6% | 37.9% | -49.6% | -27.1% | -40.6% | -35.2% | -90.0% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | 301.3% | -16.3% | -31.2% | -31.8% | -47.9% | 33.3% | |
| Diluted Shares | 498.0% | 64.3% | 50.2% | 36.3% | 493.8% | 52.8% | 2.9% | 22.4% | 48.2% | 192.8% |
Valuation
P/E (TTM)At Loss
P/S0.00
10Y Low / Med / High93.75 / 164.64 / 2155.97
P/B0.56
10Y Low / Med / High2.34 / 8.91 / 29.48
EV/EBITDAAt Loss
EV/Revenue0.00
10Y Low / Med / High88.59 / 160.47 / 2116.50
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$1.39
Tangible Book / Share
$0.45
Net Current Assets / Share
$33.68
Graham Net-Net
$0.38
Cash / Share
$0.56
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -14.74 | -17.67 | -17.84 | -27.84 | -15.24 | -38.90 | -11.50 | -8.69 | -10.61 | -1.19 | -0.01 | |
| P/S Ratio | 0.00 | 2155.97 | 93.75 | 164.64 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 13.37 | 29.48 | 8.91 | 15.80 | 5.40 | 10.92 | 5.31 | 5.05 | 2.34 | 3.25 | 0.56 | |
| EV/EBITDA | -24.45 | -16.43 | -15.95 | -26.15 | -31.93 | -39.85 | -10.92 | -8.04 | -9.88 | -0.88 | -0.87 | |
| EV/Revenue | 0.00 | 2116.50 | 88.59 | 160.47 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-22.12
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $7.7M | $36.4M | $6.5M |
| Net Income | -$27.5M | -$4.8M | -$2.4M |
| EPS | $-5.73 | $-1.01 | $-0.51 |
| # Analysts (EPS) | 1 | 1 | 1 |